Table 1.
Abundance of sEV-VEGF in ascites of women and mice with ovarian cancer
| VEGF in whole ascites (pg/mL)a | VEGF in sEV-depleted ascites (pg/mL)a | Estimated sEV-VEGF in ascites (pg/mL)b | |
|---|---|---|---|
| Ovarian cancer patient ascitesc | |||
| P1 | 2,313 | 1,435 | 878 (38.0%) |
| P2 | 1,098 | 768 | 330 (30.1%) |
| P3 | 4,056 | 3,098 | 958 (23.6%) |
| P4 | 1,837 | 1,362 | 475 (25.9%) |
| P5 | 1,930 | 1,379 | 551 (28.5%) |
| P6 | 1,118 | 708 | 410 (36.7%) |
| Ascites from mouse xenograft modelsd | |||
| M1 | 12,909 | 10,532 | 2,377 (18.4%) |
| M2 | 12,302 | 9,230 | 3,072 (25.0%) |
| M3 | 13,807 | 11,025 | 2,782 (20.1%) |
| M4 | 8,724 | 5,727 | 2,997 (34.3%) |
| M5 | 13,187 | 9,925 | 3,262 (24.7%) |
| M6 | 10,962 | 8,876 | 2,086 (19.0%) |
aAssayed by ELISA. Shown is the mean of two independent assays of each ascites sample. Source data can be found in Supplementary Data 3
bEstimated from differences between VEGF levels in whole and sEV-depleted ascites samples. Proportion shown as % of VEGF in whole ascites in parentheses
cClinical specimens of ascites from six women with Stage III high-grade serous ovarian carcinoma
dAscites from six female nude mice, collected at 3 weeks following i.p. injection of ES2 human ovarian cancer cells